Lung Cancer News and Research

Latest Lung Cancer News and Research

Syndax receives European patent allowance for entinostat to treat metastatic breast cancer

Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, today announced allowance by the European Patent Office for the patent application titled "N-(2-AMINOPHENYL)-4[N-(PYRIDINE-3-YL) - METHOXYCARBONYL - AMINOMETHYL]-BENZAMINE (MS-275) POLYMORPH B."

18 Aug 2011

Debate emerges regarding benefit of CT scans for lung cancer

Some hospitals are offering discounted CT scans to worried smokers, leading experts to question whether it's a marketing strategy or offers some health benefit.

17 Aug 2011

First Edition: August 16, 2011

Today's headlines include reports about how the influence industry is jockeying for position with the 'super committee' as well as details of how Medicaid payments for prescription drugs stack up against those made by Medicare.

16 Aug 2011

Pfizer, QIAGEN partner to develop diagnostic-therapeutic combination for NSCLC

QIAGEN today announced it has entered into a partnership with Pfizer Inc. for the development of a companion molecular diagnostic test for use with an investigational Pfizer compound in global clinical development for treatment of non-small cell lung cancer.

From QIAGEN Manchester Limited 16 Aug 2011

Survey: 35% of people in the UK fear cancer more than other life-threatening conditions

More than a third of people in the UK fear cancer more than other life-threatening conditions - such as Alzheimer's, stroke and heart disease according to a Cancer Research UK survey.

16 Aug 2011

NSAIDs like ibuprofen slow the spread of breast cancers

Published online on Aug. 7, 2011, the journal Nature Medicine reports that non-steroidal anti-inflammatory drugs including ibuprofen reduce the severity of postpartum breast cancers in animal models.

12 Aug 2011

Women worst hit by smoking

A study published in the British medical journal `The Lancet' on Thursday revealed that the risk of developing coronary heart disease is 25% higher for women smokers compared with men.

12 Aug 2011

GTx reports revenue of $1.6 million for second quarter 2011

GTx, Inc. today reported financial results for the second quarter of 2011. The net loss for the quarter ended June 30, 2011 was $10.7 million compared with a net loss of $12.9 million for the quarter ended June 30, 2010.

9 Aug 2011

Smoking first thing in the morning ‘ups’ cancer stakes

Scientists have found that people who need a cigarette within the first half hour of waking up are at a higher risk for lung, head and neck cancers. Actually this indicates a higher nicotine addiction.

8 Aug 2011

Response Genetics second quarter total revenue increases 18.8% to $6.7 million

Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced its consolidated financial results and business progress for the second quarter ended June 30, 2011.

8 Aug 2011

Leica Microsystems, CMED partner to co-develop and market automated FISH kits

China Medical Technologies, Inc. (CMED), a leading China-based advanced in-vitro diagnostic ("IVD") company, and Leica Biosystems, a division of Leica Microsystems, a world leader in microscopes and scientific instruments, today announced that they have established a sales, research and development collaboration to co-develop and market automated FISH kits to be used on the Leica BOND system.

8 Aug 2011

Study: Early morning smokers more likely to develop lung, head and neck cancer

Two new studies have found that smokers who tend to take their first cigarette soon after they wake up in the morning may have a higher risk of developing lung and head and neck cancers than smokers who refrain from lighting up right away.

8 Aug 2011

Transvaginal nephrectomy could increase rate of living donors for kidney transplants

Kidney transplant from a living donor, besides of being the best option for young people and those affected by particular conditions, results in increased organ survival and solves in part the organ shortage afflicting Spain since the mid-90 despite the high rate of cadaveric donation.

5 Aug 2011

OncoGenex second quarter revenue increases to $1.9 million

OncoGenex Pharmaceuticals, Inc. today provided an update on current events and activities and announced its second quarter financial results.

5 Aug 2011

ArQule second quarter net loss increases to $10,804,000

ArQule, Inc. today announced its financial results for the second quarter of 2011.

4 Aug 2011

ImmunoGen revenues increase to $19.3 million for fiscal year 2011

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today reported financial results for the three-month period and fiscal year ended June 30, 2011.

4 Aug 2011

Chromogenic in situ hybridization can identify ALK rearrangement in lung cancer patients

A relatively simple and inexpensive method may be used to determine whether a lung cancer patient is a candidate for crizotinib therapy, according to research published in the August issue of the Journal of Thoracic Oncology, the official monthly journal of the International Association for the Study of Lung Cancer.

3 Aug 2011

Posttraumatic stress disorder linked to persistent fears of recurrent SAH

One-third of patients who have survived a life-threatening subarachnoid hemorrhage (SAH) have disabling symptoms of posttraumatic stress disorder (PTSD), reports a study in the August issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

3 Aug 2011

Biomoda to receive European patent for porphyrin-based compound to detect cancer

Cancer diagnostics company Biomoda, Inc. received notification from the European Patent Office of its intention to grant the company's patent application related to a method of using Biomoda's proprietary porphyrin-based compound to detect cancer and pre-cancerous cells in body fluid and tissue samples.

3 Aug 2011

Pfizer second-quarter revenues decrease 1% to $17.0 billion

Pfizer Inc. today reported financial results for second-quarter 2011. As a result of Pfizer's decision to sell the Capsugel business, all revenues and expenses related to Capsugel in all periods presented are reflected in a single line, Discontinued operations - net of tax.

3 Aug 2011